Revvity
Yi-Ping Lin, Ph.D. has a significant amount of experience in the field of quality regulatory and clinical affairs. Yi-Ping currently holds the position of Senior Vice President, Chief Quality Regulatory and Clinical Officer at both Revvity and PerkinElmer, Inc. Prior to this, they served as the Senior Vice President, Quality Regulatory and Clinical Affairs at Cepheid from 2017 to 2023. Before that, they were the Vice President, Quality Assurance and Regulatory Affairs, Molecular Diagnostics at Beckman Coulter from 2014 to 2017. Yi-Ping also held various leadership positions at Abbott Laboratories, Roche Molecular Systems, Johnson & Johnson, and Roche, where they gained extensive experience in quality management and regulatory compliance.
Yi-Ping Lin, Ph.D., completed their education by obtaining a Ph.D. in Biochemistry from Rutgers University from 1986 to 1991.
This person is not in any offices
Revvity
8 followers
At Revvity, “impossible” is inspiration, and ""can't be done"" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. With more than $3 billion in revenue and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries. Learn more at www.revvity.com